Aquestive Therapeutics
Stock Forecast, Prediction & Price Target
Aquestive Therapeutics (AQST) stock Price Target by analysts
$10
Potential upside: 157.73%
Aquestive Therapeutics price prediction
What is Aquestive Therapeutics stock analysts` prediction?
Aquestive Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Aquestive Therapeutics in the last 3 months, the avarage price target is $10, with a high forecast of $NaN. The average price target represents a 157.73% change from the last price of $3.88.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Aquestive Therapeutics stock Price Target by analysts
Full breakdown of analysts given Aquestive Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Thomas Flaten Loop Capital Markets | 0% 0/2 | 10 months ago | $10 157.73% upside | $4.79 | StreetInsider | Previous targets (1) |
Thomas Flaten Loop Capital Markets | 0% 0/2 | about 1 year ago | $7 80.41% upside | $2.31 | StreetInsider | Previous targets (1) |
David Amsellem Piper Sandler | 0% 0/1 | over 1 year ago | $10 157.73% upside | $4.07 | StreetInsider | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | over 1 year ago | $9 131.95% upside | $5.51 | StreetInsider | Previous targets (0) |
Francois Brisebois Oppenheimer | 0% 0/1 | over 1 year ago | $12 209.27% upside | $6.09 | StreetInsider | Previous targets (0) |
Aquestive Therapeutics Financial Estimates
Aquestive Therapeutics Revenue Estimates
Aquestive Therapeutics EBITDA Estimates
Aquestive Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $50.83M N/A | $47.68M -6.20% | $50.58M 6.08% | Avg: $58.76M Low: $50.86M High: $63.32M avg. 16.17% | Avg: $78.21M Low: $70.96M High: $87.96M avg. 33.10% | Avg: $136.63M Low: $123.97M High: $153.66M avg. 74.69% | Avg: $193.2M Low: $175.29M High: $217.28M avg. 41.40% |
Net Income
% change YoY
| $-90.03M N/A | $-60.20M 33.13% | $-7.87M 86.92% | Avg: $-37.77M Low: $-34.30M High: $-14.70M avg. -380.04% | Avg: $-16.70M Low: $-21.43M High: $5.51M avg. 55.78% | Avg: $5.30M Low: $4.66M High: $6.16M avg. 131.77% | Avg: $36.75M Low: $32.32M High: $42.71M avg. 592.30% |
EBITDA
% change YoY
| $-34.25M N/A | $-41.96M -22.50% | $1.18M 102.81% | Avg: $-43.99M Low: $-47.41M High: $-38.08M avg. -3822.08% | Avg: $-58.55M Low: $-65.85M High: $-53.13M avg. -33.10% | Avg: $-102.29M Low: $-115.05M High: $-92.81M avg. -74.69% | Avg: $-144.64M Low: $-162.68M High: $-131.24M avg. -41.40% |
EPS
% change YoY
| -$2.36 N/A | -$1.24 47.45% | -$0.13 89.51% | Avg: -$0.42 Low: -$0.56 High: -$0.24 avg. -219.23% | Avg: -$0.16 Low: -$0.35 High: $0.09 avg. 60.64% | Avg: $0.09 Low: $0.08 High: $0.1 avg. 153.06% | Avg: $0.6 Low: $0.53 High: $0.7 avg. 592.30% |
Operating Expenses
% change YoY
| $70.52M N/A | $70.36M -0.22% | $44.85M -36.25% | Avg: $61.47M Low: $53.21M High: $66.25M avg. 37.05% | Avg: $81.82M Low: $74.24M High: $92.02M avg. 33.10% | Avg: $142.93M Low: $129.69M High: $160.76M avg. 74.69% | Avg: $202.11M Low: $183.38M High: $227.31M avg. 41.40% |
FAQ
What is Aquestive Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 99.95% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -34.30M, average is -37.77M and high is -14.70M.
What is Aquestive Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 41.34% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $50.86M, average is $58.76M and high is $63.32M.
What is Aquestive Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 146.69% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.56, average is -$0.42 and high is $-0.24.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Aquestive Therapeutics stock. The most successful analyst is Thomas Flaten.